Company Analysis GlaxoSmithKline
1. Summary
Advantages
- Dividends (3.99%) are higher than the sector average (1.28%).
- The stock's return over the last year (-3.21%) is higher than the sector average (-18.79%).
- Current debt level 28.57% is below 100% and has decreased over 5 years from 37.02%.
- The company's current efficiency (ROE=19.06%) is higher than the sector average (ROE=-83.32%)
Disadvantages
- Price (42.49 $) is higher than fair price (11.49 $)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| GlaxoSmithKline | Healthcare | Index | |
|---|---|---|---|
| 7 days | 3.1% | -14.1% | -0.6% |
| 90 days | 23.2% | -18% | 5.8% |
| 1 year | -3.2% | -18.8% | 9.1% |
GSK vs Sector: GlaxoSmithKline has outperformed the "Healthcare" sector by 15.58% over the past year.
GSK vs Market: GlaxoSmithKline has significantly underperformed the market by -12.32% over the past year.
Stable price: GSK is not significantly more volatile than the rest of the market on "New York Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.
Long period: GSK with weekly volatility of -0.0618% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (42.49 $) is higher than the fair price (11.49 $).
Price is higher than fair: The current price (42.49 $) is 73% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (21.56) is lower than that of the sector as a whole (52.65).
P/E vs Market: The company's P/E (21.56) is lower than that of the market as a whole (61.83).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (4.24) is lower than that of the sector as a whole (10.86).
P/BV vs Market: The company's P/BV (4.24) is lower than that of the market as a whole (20.82).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (1.77) is lower than that of the sector as a whole (4.03).
P/S vs Market: The company's P/S indicator (1.77) is lower than that of the market as a whole (16).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (10.32) is lower than that of the sector as a whole (16.78).
EV/Ebitda vs Market: The company's EV/Ebitda (10.32) is lower than that of the market as a whole (27.04).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -11.04% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-11.04%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-8.87%).
5.4. ROE
ROE vs Sector: The company's ROE (19.06%) is higher than that of the sector as a whole (-83.32%).
ROE vs Market: The company's ROE (19.06%) is lower than that of the market as a whole (43%).
5.5. ROA
ROA vs Sector: The company's ROA (4.35%) is lower than that of the sector as a whole (6.43%).
ROA vs Market: The company's ROA (4.35%) is lower than that of the market as a whole (23.28%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (12.84%) is lower than that of the sector as a whole (15.68%).
ROIC vs Market: The company's ROIC (12.84%) is higher than that of the market as a whole (9.2%).
7. Dividends
7.1. Dividend yield vs Market
High yield: The dividend yield of the company 3.99% is higher than the average for the sector '1.28%.
7.2. Stability and increase in payments
Dividend stability: The company's dividend yield 3.99% has been steadily paid over the past 7 years, DSI=0.79.
Weak dividend growth: The company's dividend yield 3.99% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (94.91%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
